<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16863588</article-id><article-id pub-id-type="pmc">1555599</article-id><article-id pub-id-type="publisher-id">1471-2407-6-196</article-id><article-id pub-id-type="doi">10.1186/1471-2407-6-196</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Gallo</surname><given-names>Ciro</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>ciro.gallo@unina2.it</email></contrib><contrib id="A2" contrib-type="author"><name><surname>De Maio</surname><given-names>Ermelinda</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>linda.demaio@uosc.fondazionepascale.it</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Di Maio</surname><given-names>Massimo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>massimo.dimaio@uosc.fondazionepascale.it</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Signoriello</surname><given-names>Giuseppe</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Giuseppe.Signoriello@unina2.it</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Daniele</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>bruno.daniele@ao-rummo.it</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Pignata</surname><given-names>Sandro</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>sandro.pignata@fondazionepascale.it</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Annunziata</surname><given-names>Annalisa</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>annalisa.annunziata@unina2.it</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Perrone</surname><given-names>Francesco</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>fr.perrone@agora.it</email></contrib><contrib id="A9" contrib-type="author"><on-behalf-of>the CLIP (Cancer of the Liver Italian Programme) Investigators</on-behalf-of></contrib></contrib-group><aff id="I1"><label>1</label>Department of Medicine and Public Health, Second University, Naples, Italy</aff><aff id="I2"><label>2</label>Clinical Trials Unit, National Cancer Institute, Naples, Italy</aff><aff id="I3"><label>3</label>G. Rummo Hospital, Benevento, Italy</aff><aff id="I4"><label>4</label>Medical Oncology B, National Cancer Institute, Naples, Italy</aff><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>24</day><month>7</month><year>2006</year></pub-date><volume>6</volume><fpage>196</fpage><lpage>196</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/196"></ext-link><history><date date-type="received"><day>4</day><month>5</month><year>2006</year></date><date date-type="accepted"><day>24</day><month>7</month><year>2006</year></date></history><permissions><copyright-statement>Copyright © 2006 Gallo et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Gallo et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"></ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract><sec><title><offsets xml_i="4255" xml_f="4265" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="4276" xml_f="4622" txt_i="22" txt_f="368">Large randomised clinical trials and systematic reviews substantiate that tamoxifen is ineffective in improving survival of patients with hepatocellular carcinoma (HCC). However, a recent report suggested that the drug might prolong survival among patients with well preserved liver function. The aim of this paper is to validate this hypothesis.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4663" xml_f="4670" txt_i="370" txt_f="377">Methods</offsets></title><p><offsets xml_i="4681" xml_f="4991" txt_i="378" txt_f="688">We used the updated database of the phase 3 randomised CLIP-1 trial that compared tamoxifen with supportive therapy. Primary endpoint was overall survival. Treatment arms were compared within strata defined according to the Okuda stage and the CLIP-score. Survival differences were tested by the Log-rank test.</offsets></p></sec><sec><title><offsets xml_i="5013" xml_f="5020" txt_i="690" txt_f="697">Results</offsets></title><p><offsets xml_i="5031" xml_f="5765" txt_i="698" txt_f="1432">Tamoxifen was not effective in prolonging survival in Okuda I-II subgroup (p = 0.501). Median survival times were equal to 16.8 (95%CI 12.7–18.5) months for tamoxifen and 16.8 (95%CI 13.5–22.4) months for the control arms; 1-year survival probabilities were equal to 58.8% (95%CI 51.7–65.8) and 59.4 (95%CI 52.5–66.2), respectively. Similar results were observed in the better CLIP subgroup (score 0/1), without evidence of difference between the two treatment arms (p = 0.734). Median survival times were equal to 29.2 (95%CI 20.1–36.4) months with tamoxifen and 29.0 (95%CI 23.3–35.2) months without; 1-year survival probabilities were equal to 80.9% (95%CI 72.5–89.3) with tamoxifen and 77.1% (95%CI 68.6–85.7) for the control arm.</offsets></p></sec><sec><title><offsets xml_i="5787" xml_f="5797" txt_i="1434" txt_f="1444">Conclusion</offsets></title><p><offsets xml_i="5808" xml_f="6120" txt_i="1445" txt_f="1757">The recent suggestion that tamoxifen might be effective in the subgroup of patients with better prognosis is not supported by a reanalysis of the CLIP-1 trial. Tamoxifen should no longer be considered for the treatment of HCC patients and future trials of medical treatment should concentrate on different drugs.</offsets></p></sec></abstract></article-meta></front><body><sec><title><offsets xml_i="6182" xml_f="6192" txt_i="1766" txt_f="1776">Background</offsets></title><p><offsets xml_i="6203" xml_f="6364" txt_i="1777" txt_f="1938">At the end of '90, large randomised clinical trials showed the ineffectiveness of tamoxifen in the treatment of hepatocellular carcinoma (HCC) both in advanced [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="6395" xml_f="6396" txt_i="1938" txt_f="1939">1</offsets></xref><offsets xml_i="6403" xml_f="6404" txt_i="1939" txt_f="1940">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="6435" xml_f="6436" txt_i="1940" txt_f="1941">2</offsets></xref><offsets xml_i="6443" xml_f="6479" txt_i="1941" txt_f="1977">] and potentially curable patients [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="6510" xml_f="6511" txt_i="1977" txt_f="1978">3</offsets></xref><offsets xml_i="6518" xml_f="6653" txt_i="1978" txt_f="2113">]. Since then many reviews repeatedly asserted there was no evidence of any effect of tamoxifen in improving survival of HCC patients [</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="6684" xml_f="6685" txt_i="2113" txt_f="2114">4</offsets></xref><offsets xml_i="6692" xml_f="6693" txt_i="2114" txt_f="2115">-</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="6724" xml_f="6725" txt_i="2115" txt_f="2116">9</offsets></xref><offsets xml_i="6732" xml_f="6734" txt_i="2116" txt_f="2118">].</offsets></p><p><offsets xml_i="6741" xml_f="6900" txt_i="2119" txt_f="2278">Recently, the lack of a survival advantage was further confirmed by a French trial with 420 HCC patients randomly assigned tamoxifen or supportive care alone [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="6932" xml_f="6934" txt_i="2278" txt_f="2280">10</offsets></xref><offsets xml_i="6941" xml_f="7389" txt_i="2280" txt_f="2728">]. This trial added an important piece of information because tamoxifen was found ineffective also in a HCC population with a high prevalence of alcohol-related liver cirrhosis. However, following a post-hoc unplanned subgroup analysis, the Authors suggested that tamoxifen might be effective in a population of patients without major hepatic insufficiency, i.e. those with Okuda stage I or II, and that new trials on tamoxifen are still warranted.</offsets></p><p><offsets xml_i="7396" xml_f="7478" txt_i="2729" txt_f="2811">The aim of this paper is to externally validate the hypothesis of Barbare et al. [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="7510" xml_f="7512" txt_i="2811" txt_f="2813">10</offsets></xref><offsets xml_i="7519" xml_f="7576" txt_i="2813" txt_f="2870">] using the updated data of the CLIP-1 randomised trial [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="7607" xml_f="7608" txt_i="2870" txt_f="2871">3</offsets></xref><offsets xml_i="7615" xml_f="7617" txt_i="2871" txt_f="2873">].</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="7658" xml_f="7665" txt_i="2875" txt_f="2882">Methods</offsets></title><p><offsets xml_i="7676" xml_f="7738" txt_i="2883" txt_f="2945">The methods of the CLIP-1 trial have been detailed elsewhere [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="7769" xml_f="7770" txt_i="2945" txt_f="2946">1</offsets></xref><offsets xml_i="7777" xml_f="7813" txt_i="2946" txt_f="2982">]. Brief information is given below.</offsets></p><p><offsets xml_i="7820" xml_f="8274" txt_i="2983" txt_f="3437">CLIP-1 multicenter randomised trial had a pragmatic approach with large and simple inclusion criteria: all patients with a life expectancy longer than three months and diagnosed less than two years before were eligible for the study. Differently from other studies, this trial was not limited to patients with advanced disease, thus we had the opportunity to assess the possible efficacy of treatment with tamoxifen even in potentially curable subjects [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="8305" xml_f="8306" txt_i="3437" txt_f="3438">3</offsets></xref><offsets xml_i="8313" xml_f="8315" txt_i="3438" txt_f="3440">].</offsets></p><p><offsets xml_i="8322" xml_f="8712" txt_i="3441" txt_f="3831">Patients were centrally randomised either to tamoxifen (40 mg/day) or supportive therapy using a minimization procedure with center, evidence of disease at entry and time from HCC diagnosis as stratification variables. Overall 496 subjects entered the study from 30 Italian institutions and 477 were evaluable for the analysis, 237 assigned to the tamoxifen arm, and 240 to the control arm.</offsets></p><p><offsets xml_i="8719" xml_f="8928" txt_i="3832" txt_f="4041">Overall survival was the only endpoint of the trial and analyses were performed according to an intention-to-treat basis. Survival curves were drawn by the Kaplan-Meier method and compared by the logrank test.</offsets></p><p><offsets xml_i="8935" xml_f="8980" txt_i="4042" txt_f="4087">CLIP score was estimated as reported before [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="9012" xml_f="9014" txt_i="4087" txt_f="4089">11</offsets></xref><offsets xml_i="9021" xml_f="9022" txt_i="4089" txt_f="4090">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="9054" xml_f="9056" txt_i="4090" txt_f="4092">12</offsets></xref><offsets xml_i="9063" xml_f="9179" txt_i="4092" txt_f="4208">], using Child-Pugh stage, tumor morphology, alpha fetoprotein (AFP) and portal vein thrombosis as score components.</offsets></p><p><offsets xml_i="9186" xml_f="9326" txt_i="4209" txt_f="4349">The hypothesis to be tested was that tamoxifen might be effective in patients with better prognosis, thus, according to the original study [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="9358" xml_f="9360" txt_i="4349" txt_f="4351">10</offsets></xref><offsets xml_i="9367" xml_f="9634" txt_i="4351" txt_f="4618">], two subgroups of the Okuda stage were derived (I/II and III/unknown). Similarly two subgroups of the CLIP score were obtained combining together the patients at better prognosis (scores 0 or 1) and at worse prognosis (scores equal to or greater than 2 or unknown).</offsets></p></sec><sec><title><offsets xml_i="9656" xml_f="9663" txt_i="4620" txt_f="4627">Results</offsets></title><p><offsets xml_i="9674" xml_f="9749" txt_i="4628" txt_f="4703">Distributions of baseline variables by treatment arm are reported in Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="9781" xml_f="9782" txt_i="4703" txt_f="4704">1</offsets></xref><offsets xml_i="9789" xml_f="9822" txt_i="4704" txt_f="4737">, for Okuda subgroups, and Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="9854" xml_f="9855" txt_i="4737" txt_f="4738">2</offsets></xref><offsets xml_i="9862" xml_f="9883" txt_i="4738" txt_f="4759">, for CLIP subgroups.</offsets></p><p><offsets xml_i="9890" xml_f="10218" txt_i="4760" txt_f="5088">Overall baseline variables were well balanced between the two treatment arms. As expected, more potentially curative treatments (surgery or percutaneous ethanol injection) were observed in the subgroup with the better prognosis. Less patients were classified in the better subgroup with the CLIP score than with the Okuda score.</offsets></p><p><offsets xml_i="10225" xml_f="10327" txt_i="5089" txt_f="5191">Kaplan-Meier survival curves for treatment arms, separately by Okuda subgroups are reported in Figure </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="10357" xml_f="10358" txt_i="5191" txt_f="5192">1</offsets></xref><offsets xml_i="10365" xml_f="10383" txt_i="5192" txt_f="5210"> (score I/II) and </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="10413" xml_f="10414" txt_i="5210" txt_f="5211">2</offsets></xref><offsets xml_i="10421" xml_f="11122" txt_i="5211" txt_f="5912"> (score III/unknown). In both cases tamoxifen was not effective (p = 0.501 and p = 0.650, respectively). In the first subgroup median survival times was equal to 16.8 (95%CI 12.7–18.5) months for tamoxifen and 16.8 (95%CI 13.5–22.4) months for the control arms; 1-year survival probabilities were equal to 58.8% (95%CI 51.7–65.8) and 59.4 (95%CI 52.5–66.2), respectively. Of course, in patients with Okuda stage III or unknown, prognosis was much worse, median survival times being equal to 8.9 (95%CI 5.5–14.5) months for tamoxifen and 13.1 (95%CI 6.0–28.0) months for control; 1-year survival probabilities were equal to 42.6% (95%CI 28.4–56.7) with tamoxifen and 50.8% (95%CI 35.7–65.8) without it.</offsets></p><p><offsets xml_i="11129" xml_f="11230" txt_i="5913" txt_f="6014">Kaplan-Meier survival curves for treatment arms, separately by CLIP subgroups are reported in Figure </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="11260" xml_f="11261" txt_i="6014" txt_f="6015">3</offsets></xref><offsets xml_i="11268" xml_f="11285" txt_i="6015" txt_f="6032"> (score 0/1) and </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="11315" xml_f="11316" txt_i="6032" txt_f="6033">4</offsets></xref><offsets xml_i="11323" xml_f="12136" txt_i="6033" txt_f="6843"> (score ≥2/unknown). Once again no statistically significant differences were found between the two treatment arms (p = 0.734) in the subgroup at better prognosis and (p = 0.286) in the subgroup at worse prognosis). In the first subgroup median survival times were equal to 29.2 (95% CI 20.1–36.4) months with tamoxifen and 29.0 (95% CI 23.3–35.2) months without it; 1-year survival probabilities were equal to 80.9% (95% CI 72.5–89.3) with tamoxifen and 77.1% (95% CI 68.6–85.7) for the control arm. Prognosis was worse in patients with CLIP score &gt;1 or unknown, median survival times being equal to 8.4 (95% CI 6.2–11.9) months for tamoxifen and 9.1 (95% CI 6.6–13.8) months for control; 1-year survival probabilities were equal to 41.1% (95% CI 33.2–49.0) with tamoxifen and 45.5% (95%CI 37.4–53.6) without.</offsets></p></sec><sec><title><offsets xml_i="12158" xml_f="12168" txt_i="6845" txt_f="6855">Discussion</offsets></title><p><offsets xml_i="12179" xml_f="12258" txt_i="6856" txt_f="6935">In this paper we report a failed attempt to validate the Barbare's hypothesis [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="12290" xml_f="12292" txt_i="6935" txt_f="6937">10</offsets></xref><offsets xml_i="12299" xml_f="12514" txt_i="6937" txt_f="7152">] that tamoxifen might be effective in patients with better prognosis and confirm the previous evidence that there is no survival advantage for treating HCC patients with tamoxifen in addition to supportive therapy.</offsets></p><p><offsets xml_i="12521" xml_f="12696" txt_i="7153" txt_f="7328">Because of the broad eligibility criteria applied in the CLIP-1 trial, we had already tested possible survival differences within subgroups defined by locoregional treatment [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="12727" xml_f="12728" txt_i="7328" txt_f="7329">3</offsets></xref><offsets xml_i="12735" xml_f="12864" txt_i="7329" txt_f="7458">]. Because of the strict correlation between prognosis and locoregional treatment, the present lack of significance was expected.</offsets></p><p><offsets xml_i="12871" xml_f="13039" txt_i="7459" txt_f="7627">We also tested the same hypothesis in subgroups defined according to the CLIP score, that currently is the most widely accepted and validated prognostic score for HCC [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="13071" xml_f="13073" txt_i="7627" txt_f="7629">11</offsets></xref><offsets xml_i="13080" xml_f="13081" txt_i="7629" txt_f="7630">,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="13113" xml_f="13115" txt_i="7630" txt_f="7632">12</offsets></xref><offsets xml_i="13122" xml_f="13245" txt_i="7632" txt_f="7755">]. CLIP scores 0 and 1 definitely identified patients without major hepatic insufficiency better than Okuda score (Figures </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13275" xml_f="13277" txt_i="7755" txt_f="7757">1a</offsets></xref><offsets xml_i="13284" xml_f="13289" txt_i="7757" txt_f="7762"> and </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="13319" xml_f="13321" txt_i="7762" txt_f="7764">2a</offsets></xref><offsets xml_i="13328" xml_f="13395" txt_i="7764" txt_f="7831">), but once again no evidence of tamoxifen effectiveness was found.</offsets></p><p><offsets xml_i="13402" xml_f="13882" txt_i="7832" txt_f="8312">Our results substantiate the criticism against subgroup analyses, even more urgently when they are not previously planned. In multiple subgroup analyses both more false negative results, due to the smaller size of the groups, and more false positive results, due to multiple comparisons, are expected. Exploring data in search for differences possibly depending on certain baseline characteristics may be acceptable on its own, but subgroup findings must not be over-interpreted [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="13914" xml_f="13916" txt_i="8312" txt_f="8314">13</offsets></xref><offsets xml_i="13923" xml_f="14334" txt_i="8314" txt_f="8725">]. Although the power is usually limited, only statistical tests of interaction should be performed rather than subgroup-specific tests. Anyway, the interpretation strictly depends on whether findings are biologically plausible, how many analyses are done, whether they are planned ahead and how much strong is the statistical evidence, still being aware that most subgroup claims tend to exaggerate the truth [</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="14366" xml_f="14368" txt_i="8725" txt_f="8727">13</offsets></xref><offsets xml_i="14375" xml_f="14376" txt_i="8727" txt_f="8728">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="14408" xml_f="14410" txt_i="8728" txt_f="8730">14</offsets></xref><offsets xml_i="14417" xml_f="14419" txt_i="8730" txt_f="8732">].</offsets></p><p><offsets xml_i="14426" xml_f="14638" txt_i="8733" txt_f="8945">Often, it is enough to correct for multiple testing so that results are no more statistically significant and conclusions not sounded; as would have been the case in the trial recently reported by Barbare et al [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="14670" xml_f="14672" txt_i="8945" txt_f="8947">10</offsets></xref><offsets xml_i="14679" xml_f="14681" txt_i="8947" txt_f="8949">].</offsets></p><p><offsets xml_i="14688" xml_f="14965" txt_i="8950" txt_f="9227">Although Barbare et al. discussed their findings must be regarded with great caution, their conclusion was that new trials are warranted in the specific population without major hepatic insufficiency. That conclusion brought about this report, but we failed to substantiate it.</offsets></p></sec><sec><title><offsets xml_i="14987" xml_f="14997" txt_i="9229" txt_f="9239">Conclusion</offsets></title><p><offsets xml_i="15008" xml_f="15255" txt_i="9240" txt_f="9487">In conclusion, we believe that the story of tamoxifen in HCC was definitively written; to date, neither further trials are warranted with this drug in HCC nor any use in clinical practice should be considered because of its clear lack of efficacy.</offsets></p></sec><sec><title><offsets xml_i="15277" xml_f="15296" txt_i="9489" txt_f="9508">Competing interests</offsets></title><p><offsets xml_i="15307" xml_f="15367" txt_i="9509" txt_f="9569">The author(s) declare that they have no competing interests.</offsets></p></sec><sec><title><offsets xml_i="15389" xml_f="15411" txt_i="9571" txt_f="9593">Authors' contributions</offsets></title><p><offsets xml_i="15422" xml_f="15479" txt_i="9594" txt_f="9651">CG and FP projected the study and drafted the manuscript;</offsets></p><p><offsets xml_i="15486" xml_f="15617" txt_i="9652" txt_f="9783">EDM, MDM, BD and SP participated in acquisition of data and gave substantive intellectual contribution when revising it critically;</offsets></p><p><offsets xml_i="15624" xml_f="15669" txt_i="9784" txt_f="9829">GS and AA performed the analysis of the data.</offsets></p><p><offsets xml_i="15676" xml_f="15727" txt_i="9830" txt_f="9881">All authors read and approved the final manuscript.</offsets></p></sec><sec><title><offsets xml_i="15749" xml_f="15772" txt_i="9883" txt_f="9906">Pre-publication history</offsets></title><p><offsets xml_i="15783" xml_f="15847" txt_i="9907" txt_f="9971">The pre-publication history for this paper can be accessed here:</offsets></p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/6/196/prepub"></ext-link></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Ciro Gallo has received support from AIRC (Associazione Italiana per la Ricerca sul Cancro), a non-profit charity, for studies on hepatocellular carcinoma. MDM is recipient of an AIRC fellowship. However, AIRC had no role in design, analysis and interpretation of reported data.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><collab>Cancer of the Liver Italian Program (CLIP) Group</collab></person-group><article-title>Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>17</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">9800740</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)01259-8</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>PK</given-names></name><name><surname>Tai</surname><given-names>BC</given-names></name><name><surname>Tan</surname><given-names>CK</given-names></name><name><surname>Machin</surname><given-names>D</given-names></name><name><surname>Win</surname><given-names>KM</given-names></name><name><surname>Johnson</surname><given-names>PJ</given-names></name><name><surname>Also</surname><given-names>KC</given-names></name></person-group><article-title>High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial</article-title><source>Hepatology</source><year>2002</year><volume>36</volume><fpage>1221</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12395333</pub-id><pub-id pub-id-type="doi">10.1053/jhep.2002.36824</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>F</given-names></name><name><surname>Gallo</surname><given-names>C</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name><name><surname>Gaeta</surname><given-names>GB</given-names></name><name><surname>Isso</surname><given-names>F</given-names></name><name><surname>Capuano</surname><given-names>G</given-names></name><name><surname>Adinolfi</surname><given-names>LE</given-names></name><name><surname>Mazzanti</surname><given-names>R</given-names></name><name><surname>Farinati</surname><given-names>F</given-names></name><name><surname>Elba</surname><given-names>S</given-names></name><name><surname>Piai</surname><given-names>G</given-names></name><name><surname>Calandra</surname><given-names>M</given-names></name><name><surname>Stanzione</surname><given-names>M</given-names></name><name><surname>Mattera</surname><given-names>D</given-names></name><name><surname>Aiello</surname><given-names>A</given-names></name><name><surname>De Sio</surname><given-names>I</given-names></name><name><surname>Castiglione</surname><given-names>F</given-names></name><name><surname>Russo</surname><given-names>M</given-names></name><name><surname>Persico</surname><given-names>M</given-names></name><name><surname>Felder</surname><given-names>M</given-names></name><name><surname>Manghisi</surname><given-names>OG</given-names></name><name><surname>De Maio</surname><given-names>E</given-names></name><name><surname>Di Maio</surname><given-names>M</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name></person-group><article-title>Tamoxifen in the treatment of hepatocellular carcinoma: 5 year results of the CLIP-1 multicentre randomised controlled trial</article-title><source>Current Pharmaceutical Design</source><year>2002</year><volume>8</volume><fpage>1013</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11945148</pub-id><pub-id pub-id-type="doi">10.2174/1381612024607063</pub-id></citation></ref><ref id="B4"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>A</given-names></name><name><surname>Findlay</surname><given-names>M</given-names></name><name><surname>Culjak</surname><given-names>G</given-names></name><name><surname>Stockler</surname><given-names>M</given-names></name></person-group><article-title>Tamoxifen for hepatocellular carcinoma (Cochrane Review)</article-title><source>The Cochrane Library</source><year>2006</year><publisher-name>Oxford: Update Software</publisher-name></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nowak</surname><given-names>A</given-names></name><name><surname>Stockler</surname><given-names>MR</given-names></name><name><surname>Chow</surname><given-names>PKH</given-names></name><name><surname>Findlay</surname><given-names>M</given-names></name></person-group><article-title>Use of tamoxifen in advanced-stage hepatocellular carcinoma: a systematic review</article-title><source>Cancer</source><year>2005</year><volume>103</volume><fpage>1408</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">15744746</pub-id><pub-id pub-id-type="doi">10.1002/cncr.20963</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beaugrand</surname><given-names>M</given-names></name><name><surname>N'kontchou</surname><given-names>G</given-names></name><name><surname>Seror</surname><given-names>O</given-names></name><name><surname>Ganne</surname><given-names>N</given-names></name><name><surname>Trinchet</surname><given-names>JC</given-names></name></person-group><article-title>Local/regional and systemic treatments of hepatocellular carcinoma</article-title><source>Semin Liver Dis</source><year>2005</year><volume>25</volume><fpage>201</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">15918148</pub-id><pub-id pub-id-type="doi">10.1055/s-2005-871199</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Llovet</surname><given-names>JM</given-names></name></person-group><article-title>Updated treatment approach to hepatocelluar carcinoma</article-title><source>J Gastroenterol</source><year>2005</year><volume>40</volume><fpage>225</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15830281</pub-id><pub-id pub-id-type="doi">10.1007/s00535-005-1566-3</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burroughs</surname><given-names>A</given-names></name><name><surname>Hochhauser</surname><given-names>D</given-names></name><name><surname>Meyer</surname><given-names>T</given-names></name></person-group><article-title>Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum</article-title><source>Lancet Oncol</source><year>2004</year><volume>5</volume><fpage>409</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">15231247</pub-id><pub-id pub-id-type="doi">10.1016/S1470-2045(04)01508-6</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Maio</surname><given-names>M</given-names></name><name><surname>De Maio</surname><given-names>E</given-names></name><name><surname>Perrone</surname><given-names>F</given-names></name><name><surname>Pignata</surname><given-names>S</given-names></name><name><surname>Daniele</surname><given-names>B</given-names></name></person-group><article-title>Hepatocellular carcinoma: systemic treatments</article-title><source>J Clin Gastroenterol</source><year>2002</year><volume>35</volume><fpage>S109</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">12394214</pub-id><pub-id pub-id-type="doi">10.1097/00004836-200211002-00007</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barbare</surname><given-names>JC</given-names></name><name><surname>Bouche</surname><given-names>O</given-names></name><name><surname>Bonnetain</surname><given-names>F</given-names></name><name><surname>Raoul</surname><given-names>JL</given-names></name><name><surname>Rougier</surname><given-names>P</given-names></name><name><surname>Abergel</surname><given-names>A</given-names></name><name><surname>Boige</surname><given-names>V</given-names></name><name><surname>Denis</surname><given-names>B</given-names></name><name><surname>Blanchi</surname><given-names>A</given-names></name><name><surname>Pariente</surname><given-names>A</given-names></name><name><surname>Milan</surname><given-names>C</given-names></name><name><surname>Bedenne</surname><given-names>L</given-names></name></person-group><article-title>Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>4338</fpage><lpage>4346</lpage><pub-id pub-id-type="pmid">15994145</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.05.470</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><collab>Cancer of the Liver Italian Program (CLIP) Investigators</collab></person-group><article-title>A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients</article-title><source>Hepatology</source><year>1998</year><volume>28</volume><fpage>751</fpage><lpage>755</lpage><pub-id pub-id-type="pmid">9731568</pub-id><pub-id pub-id-type="doi">10.1002/hep.510280322</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><collab>Cancer of the Liver Italian Program (CLIP) Investigators</collab></person-group><article-title>Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma</article-title><source>Hepatology</source><year>2000</year><volume>31</volume><fpage>840</fpage><lpage>845</lpage><pub-id pub-id-type="pmid">10733537</pub-id><pub-id pub-id-type="doi">10.1053/he.2000.5628</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Assmann</surname><given-names>SF</given-names></name><name><surname>Pocock</surname><given-names>SJ</given-names></name><name><surname>Enos</surname><given-names>LE</given-names></name><name><surname>Kasten</surname><given-names>LE</given-names></name></person-group><article-title>Subgroup analysis and other (mis)uses of baseline data in clinical trials</article-title><source>Lancet</source><year>2000</year><volume>355</volume><fpage>1064</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">10744093</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02039-0</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brookes</surname><given-names>ST</given-names></name><name><surname>Whitley</surname><given-names>E</given-names></name><name><surname>Peters</surname><given-names>TJ</given-names></name><name><surname>Mulheran</surname><given-names>PA</given-names></name><name><surname>Egger</surname><given-names>M</given-names></name><name><surname>Davey Smith</surname><given-names>G</given-names></name></person-group><article-title>Subgroup analyses in randomised controlled trials: Quantifying the risks of false-positive and false-negatives</article-title><source>Health Technology Assessment</source><year>2001</year><volume>5</volume><pub-id pub-id-type="pmid">11701102</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig position="float" id="F1"><label>Figure 1</label><caption><p>Kaplan-Meier estimated survival curves by treatment arm, according to Okuda subgroups I/II.</p></caption><graphic xlink:href="1471-2407-6-196-1"></graphic></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Kaplan-Meier estimated survival curves by treatment arm, according to Okuda subgroups III/unknown.</p></caption><graphic xlink:href="1471-2407-6-196-2"></graphic></fig><fig position="float" id="F3"><label>Figure 3</label><caption><p>Kaplan-Meier estimated survival curves by treatment arm, according to CLIP subgroups 0/1.</p></caption><graphic xlink:href="1471-2407-6-196-3"></graphic></fig><fig position="float" id="F4"><label>Figure 4</label><caption><p>Kaplan-Meier estimated survival curves by treatment arm, according to CLIP subgroups &gt;1/unknown.</p></caption><graphic xlink:href="1471-2407-6-196-4"></graphic></fig><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Distributions of baseline variables by treatment arm, according to prognostic Okuda subgroups</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>
                           <italic>Okuda category</italic>
                        </bold></td><td align="center" colspan="2"><bold>I-II</bold></td><td align="center" colspan="2"><bold>III or unknown</bold></td></tr></thead><tbody><tr><td></td><td align="center"><bold>Tamoxifen (n = 189)</bold></td><td align="center"><bold>Control (n = 196)</bold></td><td align="center"><bold>Tamoxifen (n = 48)</bold></td><td align="center"><bold>Control (n = 44)</bold></td></tr><tr><td align="left">Median (range) age, <italic>years</italic></td><td align="center">66 (39–91)</td><td align="center">67 (42–84)</td><td align="center">62 (37–86)</td><td align="center">66 (31–80)</td></tr><tr><td align="left">Men</td><td align="center">133 (70.4)</td><td align="center">144 (73.5)</td><td align="center">36 (75.0)</td><td align="center">39 (88.6)</td></tr><tr><td align="left">Evidence of disease at entry</td><td align="center">178 (94.2)</td><td align="center">184 (93.9)</td><td align="center">40 (83.3)</td><td align="center">39 (88.6)</td></tr><tr><td align="left">Interval between diagnosis and entry</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 0–6 months</td><td align="center">150 (79.4)</td><td align="center">161 (82.1)</td><td align="center">44 (91.7)</td><td align="center">38 (86.7)</td></tr><tr><td align="left"> 7–12 months</td><td align="center">20 (10.6)</td><td align="center">15 (7.7)</td><td align="center">1 (2.1)</td><td align="center">4 (9.1)</td></tr><tr><td align="left"> 13–24 months</td><td align="center">19 (10.1)</td><td align="center">20 (10.2)</td><td align="center">6 (6.3)</td><td align="center">2 (4.6)</td></tr><tr><td align="left">Child-Pugh category</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> A</td><td align="center">90 (47.6)</td><td align="center">98 (50.0)</td><td align="center">25 (52.1)</td><td align="center">20 (45.6)</td></tr><tr><td align="left"> B</td><td align="center">82 (43.4)</td><td align="center">75 (38.3)</td><td align="center">13 (27.1)</td><td align="center">11 (25.0)</td></tr><tr><td align="left"> C</td><td align="center">17 (9.0)</td><td align="center">23 (11.7)</td><td align="center">9 (18.8)</td><td align="center">12 (27.3)</td></tr><tr><td align="left"> unknown</td><td align="center">0 (0.0)</td><td align="center">0 (0.0)</td><td align="center">1 (2.1)</td><td align="center">1 (2.3)</td></tr><tr><td align="left">Locoregional treatment</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> Surgery</td><td align="center">11 (5.8)</td><td align="center">12 (6.1)</td><td align="center">7 (14.6)</td><td align="center">3 (6.8)</td></tr><tr><td align="left"> Percutaneous Ethanol Injection</td><td align="center">61 (32.3)</td><td align="center">72 (36.7)</td><td align="center">3 (6.3)</td><td align="center">6 (13.6)</td></tr><tr><td align="left"> Transarterial chemoembolization</td><td align="center">31 (16.4)</td><td align="center">33 (16.8)</td><td align="center">11 (22.9)</td><td align="center">5 (11.4)</td></tr><tr><td align="left"> none</td><td align="center">86 (45.5)</td><td align="center">79 (40.3)</td><td align="center">27 (56.3)</td><td align="center">30 (68.2)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Distributions of baseline variables by treatment arm, according to prognostic CLIP subgroups</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>
                           <italic>Clip category</italic>
                        </bold></td><td align="center" colspan="2"><bold>
                           <italic>0–1</italic>
                        </bold></td><td align="center" colspan="2"><bold>
                           <italic>2–6 or unknown</italic>
                        </bold></td></tr></thead><tbody><tr><td></td><td align="center"><bold>Tamoxifen (n = 85)</bold></td><td align="center"><bold>Control (n = 94)</bold></td><td align="center"><bold>Tamoxifen (n = 152)</bold></td><td align="center"><bold>Control (n = 146)</bold></td></tr><tr><td align="left">Median (range) age (years)</td><td align="center">66 (37–91)</td><td align="center">66 (31–80)</td><td align="center">65 (39–86)</td><td align="center">67 (42–84)</td></tr><tr><td align="left">Men</td><td align="center">57 (67.1)</td><td align="center">68 (72.3)</td><td align="center">112 (73.7)</td><td align="center">115 (78.8)</td></tr><tr><td align="left">Evidence of disease at entry</td><td align="center">77 (90.6)</td><td align="center">86 (91.5)</td><td align="center">141 (92.8)</td><td align="center">137 (93.8)</td></tr><tr><td align="left">Interval between diagnosis and entry</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> 0–6 months</td><td align="center">85 (100.0)</td><td align="center">94 (100.0)</td><td align="center">109 (71.7)</td><td align="center">105 (71.9)</td></tr><tr><td align="left"> 7–12 months</td><td align="center">0 (0.0)</td><td align="center">0 (0.0)</td><td align="center">21 (13.8)</td><td align="center">19 (13.0)</td></tr><tr><td align="left"> 13–24 months</td><td align="center">0 (0.0)</td><td align="center">0 (0.0)</td><td align="center">22 (14.5)</td><td align="center">22 (15.1)</td></tr><tr><td align="left">Child-Pugh category</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> A</td><td align="center">62 (72.9)</td><td align="center">67 (71.3)</td><td align="center">53 (34.9)</td><td align="center">51 (34.9)</td></tr><tr><td align="left"> B</td><td align="center">23 (27.1)</td><td align="center">27 (28.7)</td><td align="center">72 (47.4)</td><td align="center">59 (40.4)</td></tr><tr><td align="left"> C</td><td align="center">0 (0.0)</td><td align="center">0 (0.0)</td><td align="center">26 (42.6)</td><td align="center">35 (24.0)</td></tr><tr><td align="left"> unknown</td><td align="center">0 (0.0)</td><td align="center">0 (0.0)</td><td align="center">1 (0.7)</td><td align="center">1 (0.7)</td></tr><tr><td align="left">Locoregional treatment</td><td></td><td></td><td></td><td></td></tr><tr><td align="left"> Surgery</td><td align="center">10 (11.8)</td><td align="center">10 (10.6)</td><td align="center">8 (5.3)</td><td align="center">5 (3.4)</td></tr><tr><td align="left"> Percutaneous Ethanol Injection</td><td align="center">34 (40.0)</td><td align="center">46 (48.9)</td><td align="center">30 (19.7)</td><td align="center">32 (21.9)</td></tr><tr><td align="left"> Transarterial chemoembolization</td><td align="center">18 (21.2)</td><td align="center">17 (18.1)</td><td align="center">24 (15.8)</td><td align="center">21 (14.4)</td></tr><tr><td align="left"> none</td><td align="center">23 (27.1)</td><td align="center">21 (22.3)</td><td align="center">90 (59.2)</td><td align="center">88 (60.3)</td></tr></tbody></table></table-wrap></sec></back></article>